Learn about the latest in SCLC Research from Misty Shields, MD, PhD, Thoracic Medical Oncologist, Assistant Professor of Clinical Medicine, & Associate Member, Experimental & Developmental Therapeutics at Indiana University School of Medicine and Indiana University Health Physicians.
This video was recorded during the LiveLung Small Cell Lung Cancer meeting on October 9, 2024.
Subscribe to our YouTube channel and click the notification bell so you know when new educational lung cancer videos are available https://www.youtube.com/livelung
About the Speaker Misty Shields, PD, PhD
Thoracic Medical Oncologist, Assistant Professor of Clinical Medicine, & Associate Member, Experimental & Developmental Therapeutics at Indiana University School of Medicine and Indiana University Health Physicians
Dr. Misty Dawn Shields is a thoracic medical oncologist, assistant professor of clinical medicine, and associate member of experimental and developmental therapeutics at Indiana University School of Medicine and Indiana University Health Physicians. The fight against lung cancer is personal. She lost her father to small cell lung cancer when she was 15 years old. After losing her father, she sought to better understand every piece of bench-to-bedside precision medicine for lung cancer. Dr. Shields trained with world-renowned translational oncologist Dr. John Minna, where her graduate studies helped to identify predictive biomarkers to pemetrexed in non-small cell lung cancer. In collaboration with the laboratory of Dr. Melanie Cobb, she contributed to the discovery of NeuroD1 as a neuroendocrine subtype in small cell lung cancer. To serve at the bedside and care for patients experiencing similar afflictions to her father, Dr. Shields steadfastly pursued her medical training at UT Houston, including rotations at MD Anderson Cancer Center, internal medicine residency at Vanderbilt University, hematology/oncology fellowship at H. Lee Moffitt Cancer Center as chief fellow, and the FDA-AACR Oncology Educational fellowship. She joined faculty at Indiana University in August 2022 as a physician scientist with a focus in early phase trials, longitudinal liquid biopsies, and translational studies for novel therapeutics in acquired chemo-resistant SCLC as principal investigator of the Shields lab. Dr. Shields serves on the guideline panel for SCLC with the National Comprehensive Cancer Network, local leadership board for American Lung Association, and as the clinical trials advocate for IU Simon Comprehensive Cancer Center’s End Lung Cancer Now. Dr. Shields serves as the founder of the Small Cell SMASHERS patient advocacy group in partnership with Lungevity Foundation.
The LiveLung Small Cell Lung Cancer Program is supported in-part by grants from AstraZeneca, Amgen, and Jazz Pharmaceutical.
This Video Content has been made available for informational and educational purposes only. The Video Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on the Site.
LiveLung and speakers hereby disclaim any and all liability to any party for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising directly or indirectly from any use of the Video Content, which is provided as is, and without warranties.